gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Interleukin 6 receptor

IL-6R, interleukin-6 receptor, gp80, IL-6Ralpha
This gene encodes a subunit of the interleukin 6 (IL6) receptor complex. Interleukin 6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. The IL6 receptor is a protein complex consisting of this protein and interleukin 6 signal transducer (IL6ST/GP130/IL6-beta), a receptor subunit also shared by many other cytokines. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been reported. A pseudogene of this gene is found on chromosome 9.[provided by RefSeq, May 2011] (from NCBI)
Top mentioned proteins: Interleukin-6, NMDA receptor, CAN, STAT3, V1a
Papers using IL-6R antibodies
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Sesti Giorgio, In PLoS ONE, 1997
... used anti-cytokines antibodies against IL-1ß, IL-6, TNFα, IFNγ, and anti-cytokine receptor antibodies against IL-1R1, IL-1R2, IL-6R, TNF-R1, IFN-Rα, IFN-Rß (Santa Cruz Biotechnology, Santa Cruz, CA); guinea ...
Papers on IL-6R
Hypersensitivity reactions during treatment with biological agents.
Migliorini et al., Pisa, Italy. In Clin Exp Rheumatol, Feb 2016
UNASSIGNED: The recent development of biological agents, namely, anti-tumour necrosis factor alpha (TNF-α) agents (infliximab, adalimumab and etanercept), anti- CD20 monoclonal antibody (rituximab) and anti-interleukin 6 receptor (IL-6R) monoclonal antibody (tocilizumab), represents a major breakthrough for the treatment of immune-mediated disorders.
Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal.
Mittal et al., Detroit, United States. In Oncotarget, Feb 2016
IL-17 also induced cytokine/chemokine (IL-6, IL-8, interferon-γ-inducible protein [IP-10], and monocyte chemoattractant protein-1 [MCP-1]) secretion in GSCs, which were differentially blocked by antibodies against IL-17R and IL-6R.
IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3.
Metcalfe et al., Bethesda, United States. In J Allergy Clin Immunol, Feb 2016
CONCLUSION: IL-6 increases MC proliferation and formation of a more reactive phenotype enabled by suppressing proteolytic cleavage of sIL-6R from IL-6R and downregulation of the SOCS3 autoinhibitory pathway.
IL-30 (IL27p28) alleviates sepsis via modulation of cytokine profiles produced by NKT cells.
Li et al., Houston, United States. In J Hepatol, Feb 2016
Blocking IL-6R or gp130 inhibited IL-30 mediated IL-10 production.
Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
Yanaba, Tokyo, Japan. In J Dermatol, Jan 2016
immunoglobulins, B-cell depletion, anti-interleukin-6 receptor antibody, autologous hematopoietic stem cell transplantation, rapamycin, pirfenidone and imatinib mesylate are potential candidates for the treatment of SSc, although their efficacy has not been validated.
Endogenous IL-6 of mesenchymal stem cell improves behavioral outcome of hypoxic-ischemic brain damage neonatal rats by supressing apoptosis in astrocyte.
Chen et al., Chongqing, China. In Sci Rep, Dec 2015
In vitro, the levels of IL-6 release and the levels of IL-6R and STAT3 expression were increased in both primary neurons and astrocytes subjected to oxygen and glucose deprivation (OGD) following MSCs co-culture.
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.
Gold et al., Bochum, Germany. In Neurotherapeutics, Dec 2015
B-cell depletion with rituximab and other agents, inhibition of the interleukin-6 receptor with tocilizumab, and blockade of complement-mediated damage by eculizumab all are promising therapeutic strategies evaluated in randomized controlled trials.
T Follicular Helper Cell-Dependent Clearance of a Persistent Virus Infection Requires T Cell Expression of the Histone Demethylase UTX.
Su et al., Chapel Hill, United States. In Immunity, Nov 2015
UTX-deficient T cells showed decreased expression of interleukin-6 receptor-α and other Tfh cell-related genes that were associated with increased H3K27 methylation.
The soluble interleukin-6 receptor and related proteins.
Rose-John, Kiel, Germany. In Best Pract Res Clin Endocrinol Metab, Oct 2015
Interleukin-6 binds to an interleukin-6 receptor, and then associates with a dimer of the ubiquitously expressed gp130 receptor subunit, which initiates intracellular signaling.
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Hill et al., Brisbane, Australia. In Lancet Oncol, 2014
Immune reconstitution was preserved in recipients of interleukin-6 receptor inhibition, but qualitatively modified with suppression of known pathogenic STAT3-dependent pathways.
Regulatory T cells in Arthritis.
Takayanagi et al., Tokyo, Japan. In Prog Mol Biol Transl Sci, 2014
The importance of Treg cells in RA is supported by the effectiveness of CTLA4-Ig therapy, an increased Treg cell/effector T cell ratio after anti-IL-6R or anti-TNF-α treatment and the identification of CTLA-4 as an RA-associated gene.
Association of phosphodiesterase 4D gene and interleukin-6 receptor gene polymorphisms with ischemic stroke in a Chinese hypertensive population.
Sun et al., Shenyang, China. In Genet Mol Res, 2014
The aim of the present study was to explore the association between the phosphodiesterase 4D gene (PDE4D) and interleukin-6 receptor gene (IL6R) single nucleotide polymorphisms and ischemic stroke in a hypertensive population.
Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production.
Mauri et al., Udine, Italy. In Nat Med, 2014
Mice lacking IL-6 receptor (IL-6R) or IL-1 receptor 1 (IL-1R1) specifically on B cells have a reduced number of IL-10-producing B cells and develop exacerbated arthritis compared to control animals.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Grupp et al., Australia. In N Engl J Med, 2014
Severe cytokine-release syndrome, which developed in 27% of the patients, was associated with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.
Metalloproteinases and their natural inhibitors in inflammation and immunity.
Weiss et al., Toronto, Canada. In Nat Rev Immunol, 2013
Together with their endogenous inhibitors TIMPs (tissue inhibitor of metalloproteinases), these enzymes regulate signalling downstream of the tumour necrosis factor receptor and the interleukin-6 receptor, as well as that downstream of the epidermal growth factor receptor and Notch, which are all pertinent for inflammatory responses.
The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma.
National Heart et al., Winston-Salem, United States. In J Allergy Clin Immunol, 2012
The IL6R coding SNP rs2228145 (Asp358Ala) is a potential modifier of lung function in subjects with asthma and might identify subjects at risk for more severe asthma.
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
Shin et al., South Korea. In Int J Oncol, 2012
IL-6R is present in cancer stem cells and has an important role in the proliferation
Interleukin-6 receptor α is co-localised with melanin-concentrating hormone in human and mouse hypothalamus.
Jansson et al., Göteborg, Sweden. In J Neuroendocrinol, 2012
Il6r alpha is co-localized with melanin-concentrating hormone in mouse hypothalamus.
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Danesh et al., In Lancet, 2012
We assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6.
Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation.
Banas et al., Regensburg, Germany. In Cytokine, 2012
Elevated urinary concentrations of IL6, sIL6R, TNFR1 and sVCAM-1 clearly indicate an early acute transplant rejection.
share on facebooktweetadd +1mail to friends